Better survival and prognosis in SCLC survivors after combined second primary malignancies: A SEER database-based study

With recent advances in treatment modalities, the survival time for patients with small cell lung cancer (SCLC) has increased, along with the likelihood of recurrence of a second primary tumor. However, patient treatment options and prognosis remain uncertain. This research evaluated the survival rates of patients with SCLC with a second malignancy, aiming to provide new insights and statistics on whether to proceed with more active therapy. SCLC patients were selected based on the Surveillance, Epidemiology, and End Results (SEER) database, updated on April 15, 2021. We defined those with SCLC followed by other cancers (1st of 2 or more primaries) in the sequence number as S-second primary malignant cancer (S-SPM). Those who had other cancers followed by SCLC (2nd of 2 or more primaries) were defined as OC-SCLC. We performed Kaplan–Meier survival analysis, life table analysis, univariate analysis, stratified analysis, and multiple regression analysis of patient data. We considered the difference statistically meaningful at P < .05. After selection, data for 88,448 participants from the SEER database was included in our analysis. The mean survival time for patients with S-SPM was 69.349 months (95% confidence interval [CI]: 65.939, 72.759), and the medium duration of survival was 34 months (95% CI: 29.900, 38.100). Univariate analysis showed that for overall survival, the hazard ratio (HR) of S-SPM was 0.367 (95% CI: 0.351, 0.383), which was 0.633 lower than that of patients with solitary SCLC and 0.606 lower than that of patients with OC-SCLC. For cancer-specific survival (CSS), the HR of S-SPM was 0.285 (95% CI: 0.271, 0.301), which was 0.715 lower than for patients with solitary SCLC and 0.608 lower than that for patients with OC-SCLC. Multiple regression analysis showed that the HR values of S-SPM were lower than those of patients with single SCLC and those with OC-SCLC, before and after adjustment for variables. Kaplan–Meier survival curves showed that patients with S-SPM had significantly better survival times than the other groups. The survival time and prognosis of patients with S-SPM were clearly superior to those with single SCLC and OC-SCLC.

[1]  B. Suktitipat,et al.  Risks and cancer associations of metachronous and synchronous multiple primary cancers: a 25-year retrospective study , 2021, BMC Cancer.

[2]  X. Zu,et al.  N6-Methyladenosine Writer Gene ZC3H13 Predicts Immune Phenotype and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma , 2021, Frontiers in Oncology.

[3]  H. Bach,et al.  Current and Future Development in Lung Cancer Diagnosis , 2021, International journal of molecular sciences.

[4]  O. Slabý,et al.  Second primary malignancies in colorectal cancer patients , 2021, Scientific Reports.

[5]  J. Minna,et al.  Evasion of Innate Immunity Contributes to Small Cell Lung Cancer Progression and Metastasis , 2021, Cancer Research.

[6]  Jingxiao Lu,et al.  Predictive value of protease‐activated receptor‐2 (PAR2) in cervical cancer metastasis , 2020, Journal of cellular and molecular medicine.

[7]  J. Sage,et al.  Mechanisms of small cell lung cancer metastasis , 2020, EMBO molecular medicine.

[8]  C. Rudin,et al.  Advances in Small-Cell Lung Cancer (SCLC) Translational Research. , 2020, Cold Spring Harbor perspectives in medicine.

[9]  G. Fabbrocini,et al.  Second primary melanoma: incidence rate and risk factors , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[10]  A. Haydaroǧlu,et al.  Trends in the incidence and overall survival of multiple primary cancers in Turkey. , 2020, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[11]  Huixun Jia,et al.  Second Primary Malignancies in Patients with Colorectal Cancer: A Population‐Based Analysis , 2020, The oncologist.

[12]  Fang Wang,et al.  Resection of Early-Stage Second Primary Non-small Cell Lung Cancer After Small Cell Lung Cancer: A Population-Based Study , 2020, Frontiers in Oncology.

[13]  S. Rogers,et al.  Incidence, timing, presentation, treatment, and outcomes of second primary head and neck squamous cell carcinoma after oral cancer. , 2019, The British journal of oral & maxillofacial surgery.

[14]  A. Mansfield,et al.  Current Diagnosis and Management of Small-Cell Lung Cancer. , 2019, Mayo Clinic proceedings.

[15]  M. Copur,et al.  Multiple Primary Tumors Over a Lifetime. , 2019, Oncology.

[16]  M. Galanopoulos,et al.  Advanced small cell lung cancer (SCLC): new challenges and new expectations. , 2018, Annals of translational medicine.

[17]  C. Rudin,et al.  Small Cell Lung Cancer , 2016, Seminars in Respiratory and Critical Care Medicine.

[18]  F. Koinis,et al.  Small cell lung cancer (SCLC): no treatment advances in recent years. , 2016, Translational lung cancer research.

[19]  I. Wistuba,et al.  Diagnosis and Molecular Classification of Lung Cancer. , 2016, Cancer treatment and research.

[20]  Marta S. Patrucco,et al.  Prognostic impact of second primary tumors in head and neck cancer , 2016, European Archives of Oto-Rhino-Laryngology.

[21]  S. Holm,et al.  Incidence of Second Primary Malignancies in Patients with Neuroendocrine Tumours , 2015, Neuroendocrinology.

[22]  S. Narod,et al.  Multiple primary cancers as a guide to heritability , 2014, International journal of cancer.

[23]  A. Carvalho,et al.  Second primary tumor in patients with upper aerodigestive tract cancer , 2010, Brazilian journal of otorhinolaryngology.

[24]  J. Coebergh,et al.  Epidemiology of multiple primary cancers. , 2009, Methods in molecular biology.

[25]  M. Porta,et al.  Multiple independent primary cancers do not adversely affect survival of the lung cancer patient. , 2008, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[26]  M. Nakashima,et al.  Incidence of multiple primary cancers in Nagasaki atomic bomb survivors: Association with radiation exposure , 2007, Cancer science.

[27]  M. Stokkel,et al.  Second primary tumors involving non-small cell lung cancer: prevalence and its influence on survival. , 2005, Chest.

[28]  K. Hemminki,et al.  Multiple primary cancers as clues to environmental and heritable causes of cancer and mechanisms of carcinogenesis. , 2004, IARC scientific publications.

[29]  C. Link,et al.  The etiology of second primary neoplasms. , 1998, In vivo.

[30]  K. Dieckmann,et al.  Multiple primary neoplasms in patients with testicular germ cell tumor. , 1994, Oncology.

[31]  S. Lippman,et al.  The incidence of second primary tumors in long-term survivors of small-cell lung cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.